Thrombin generation and endothelial progenitor cell function among patients with acute myocardial infarction treated with prasugrel versus ticagrelor
نویسندگان
چکیده
Abstract Objectives To compare the effects of prasugrel and ticagrelor on thrombin generation (TG) circulating endothelial progenitor cells (EPCs) in acute phase ST-segment elevation myocardial infarction (STEMI). Background TG, platelet function EPCs have an important role pathophysiology coronary artery disease (CAD). date, effect novel P2Y12 inhibitors these coagulation mediators has only been studied sub-acute following infarction. Methods Patients presenting with STEMI undergoing primary percutaneous intervention (PPCI) were randomized to either or treatment. reactivity EPC tested prior inhibitor loading dose (T0), 24 hours PPCI (T1). Results Between December 2018 July 2021, 83 consecutive patients (N=42) (N=41) No differences observed at T0 for all measurements. At T1, was found be a more potent TG inhibitor: lower peak levels (319.5±237.7 nmol/L vs. 433.5±264.3 nmol/L, p=0.06), longer time (14.1±12.6 min 8.3±9.7 min, p=0.03), lag initiation (7.7±7.5 3.9±2.1 p<0.01) smaller AUC (2186.1±1123.1 3362.5±2108.5, p<0.01). Furthermore, CD34 (2.6±4.1 1.1±1.1, p=0.01), CD133 (2.3±1.8 1.4±1.5, p=0.01) CFUs (2.1±1.5 1.1±1.0, significantly higher group, as compared group. Conclusion Among treated PPCI, treatment associated inhibition improved count function. Funding Acknowledgement Type funding sources: None.
منابع مشابه
Prasugrel Versus ticagrelor in Patients With acute Myocardial infarction treated With Primary Percutaneous coronary intervention
متن کامل
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
BACKGROUND No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. METHODS This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with pr...
متن کاملRandomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
BACKGROUND Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction patients. METHODS AND RESULTS In a prospective, single-center, single-blind study, 55 out of 117 (47%) screened consecutive ST-segment-elevation myocardial infarction patients ...
متن کاملErythropoietin, Hemoglobin and Endothelial Progenitor Cell Levels in Patients with Acute Myocardial Infarction
We investigated whether changes in plasmatic erythropoietin (Epo) levels in patients with acute myocardial infarction (AMI) reflect changes in hemoglobin (Hb) levels. We studied plasma Epo levels and their relation with Hb and endothelial progenitors in patients with AMI and in patients with unstable angina (UAP). Seventeen AMI patients undergoing percutaneous coronary intervention (PCI) within...
متن کاملOutcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
AIMS Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs. clopidogrel. We wished to study clinical outcomes in a large real-world population post-ACS. METHODS AND RESULTS We performed a prospective cohort study in 45 073 ACS patients enrolled into Swedish Web system for Enhancement and Development of Evidence-based care in Heart Disease Evaluated According to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2022
ISSN: ['2634-3916']
DOI: https://doi.org/10.1093/eurheartj/ehac544.1238